Skip to main content
. 2014 Jun 5;9(6):e98689. doi: 10.1371/journal.pone.0098689

Table 3. Comparison of patients with and without discordance.

Variables Patients without discordance(n = 148, 91.9%) Patients with discordance(n = 13, 8.1%) P value
Demographic variables
Age (years) 49 (18–81) 52 (35–70) NS
Male gender 95 (64.2) 7 (53.8) NS
Body mass index (kg/m2) 24.4 (14.3–34.3) 24.5 (21.6–29.8) NS
Diabetes mellitus 23 (15.5) 5 (38.5) NS
Etiology, NAFLD/HBV/HCV/Others 64 (43.9)/45 (30.4)/26 (17.6)/12 (8.1) 7 (53.8)/4 (30.8)/2 (15.4)/0 (0.0) NS
Biochemical parameters
Aspartate aminotransferase (IU/L) 46.1±37.1 34.5±21.2 NS
Alanine aminotransferase (IU/L) 50.9±45.0 36.6±25.8 NS
Serum albumin (g/dL) 4.1±0.5 4.2±0.4 NS
Fasting glucose (mg/mL) 108.2±34.6 124.0±39.5 NS
Total cholesterol (mg/mL) 171.5±40.9 180.1±36.0 NS
Triglycerides (mg/mL) 126.2±60.4 153.7±54.9 NS
Liver biopsy
Fibrosis stage
F0–2/F3–4 99 (66.9)/49 (33.1) 10 (76.9)/3 (23.1) NS
Activity grade
A0–2/A3 114 (77.0)/34 (23.0) 9 (69.2)/4 (30.8) NS
Steatosis
S0–2/S3 144 (97.3 )/4 (2.7) 11 (84.6)/2 (15.4) 0.021
Biopsy length (cm) 18.2 (16.4–24.2) 18.6 (16.1–23.5) NS
Liver stiffness measurement
Liver stiffness value (kPa) 8.2 (2.9–75.0) 7.4 (3.0–17.5) NS
Interquartile range (kPa) 1.0 (0.1–14.0) 1.5 (0.4–2.6) NS
IQR/M 0.12 (0.01–0.35) 0.15 (0.06–0.26) NS
Controlled attenuation parameter
Controlled attenuation parameter value (dB/m) 250 (149–400) 327 (230–345) 0.010
Interquartile range (dB/m) 29.0 (6–72) 30.0 (15–76) NS
IQR/MCAP 0.12 (0.02–0.28) 0.10 (0.05–0.33) NS

Variables are expressed as median (range) or n (%).

NS, not significant; NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B; HCV, hepatitis C; kPa, kilopascal; IQR/M, interquartile range/median liver stiffness value; CAP, controlled attenuation parameter; IQR/MCAP, interquartile range/median of CAP value.